Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05935358 · ClinicalTrials.gov registry record · Phase 4
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
A Phase 4 study of Severe Hemophilia A, sponsored by Octapharma.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
- 18
- Study locations
NCT05935358 is a Phase 4 study of Severe Hemophilia A that is actively recruiting participants, run by Octapharma. The registered enrollment target is 28 participants, below the 64-participant average among 4 other Severe Hemophilia A trials with a reported enrollment target (56% lower). The trial reports 18 study locations across 3 states.
The verdict
NCT05935358, a Phase 4 study of Severe Hemophilia A, is actively recruiting participants, sponsored by Octapharma.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
- 18
- Study locations
Study Summary
Recombinant factor VIII for the prevention of bleeding in patients with severe haemophilia A undergoing major surgery while receiving emicizumab prophylaxis
Conditions Studied
Interventions
- DRUG Nuwiq
Study Locations (18)
Other
- University Hospital Centre Zagreb - Zagreb
- Helsinki University Hospital - Helsinki
- CHU de Nantes Hôtel-Dieu - Nantes
- CHRU de Tours - Tours
- Vivantes Klinikum im Friedrichshein (KFH) - Berlin
- Gerinnungszentrum Rhein-Ruhr - Duisburg
- Universitätsklinikum Hamburg Eppendorf (UKE) - Hamburg
- St. John's Medical College Hospital - Bengaluru
- Azienda Ospedaliera Pugliese Ciaccio - Catanzaro
- Azienda Ospedaliero Universitaria Careggi - Centro Emofilia - Florence
- Centro Trombosi e Malattie Emorragiche, ITCCS Humanitas Research Hospital - Milan
- Centre for Haemopilia, Institute for transfusion medicine of Republic of North Macedonia - Skopje
- Clinical Center for Serbia Belgrade - Belgrade
- Hospital Universitario La Paz - Madrid
- Hospital Universitario Virgen del Rocio - Seville
- St. James's University Hospital - Leeds
Texas
- UT Southwestern Medical Center - Dallas
Tamil Nadu
- Christian Medical College Vellore - Vellore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-11-28 |
| Est. Completion | 2026-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05935358
The ClinicalTrials.gov registry entry for NCT05935358 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 64-participant average among 4 other Severe Hemophilia A trials with a reported enrollment target (56% lower). The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Severe Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which Nuwiq is the first listed.
NCT05935358 reports 18 study locations spanning 3 distinct geographic areas - top geographies include Other, Texas, Tamil Nadu.
Frequently Asked Questions
What is clinical trial NCT05935358 about?
NCT05935358 is a clinical study titled "Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study". Recombinant factor VIII for the prevention of bleeding in patients with severe haemophilia A undergoing major surgery while receiving emicizumab prophylaxis
What is the current status of trial NCT05935358?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2023-11-28. Estimated completion is 2026-08.
What conditions does trial NCT05935358 study?
This clinical trial studies the following conditions: Severe Hemophilia A.
What interventions are being tested in trial NCT05935358?
The interventions under investigation include: Nuwiq (DRUG).
Who is sponsoring clinical trial NCT05935358?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05935358 being conducted?
This trial has 18 study locations across Texas, Tamil Nadu. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
ACTIVE NOT RECRUITING · Phase 4
-
A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
RECRUITING · Phase 1
-
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
ACTIVE NOT RECRUITING · Phase 3
-
Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.